美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

百濟神州

219.95

-4.7800-2.13%

盤後：219.950.00000.00%18:20 EDT

成交量：26.28萬

成交額：5,823.34萬

市值：237.67億

市盈率：-59.39

高：225.91

開：223.20

低：218.31

收：224.73

資料載入中...

總覽公司新聞資訊公告

異動解讀 | 百濟神州股價盤前大跌5.25%，Q1財報虧損遠超預期

百濟神州第一季度淨利虧損9450.3萬元，同比大幅減虧

百濟神州(688235.SH)一季度營業總收入80.48億元，同比增長50.2%

百濟神州首次實現季度GAAP盈利一季度澤布替尼全球銷售額超50億元

百濟神州（06160）2025Q1強勁增長首次實現季度GAAP盈利

A股公告精選 | 百濟神州(688235.SH)第一季度營業利潤、利潤總額由虧轉盈

智通财经网

百濟神州：第一季度淨虧損9450.3萬元

每日经济新闻

百濟神州Q1營收增長50.2%至80.48億元，百悅澤®全球銷售額總計56.92億

百濟神州、宜聯新藥IND！禮來重金加註、AZ聯合療法新進展

医药经济报

【百濟神州：2025年第一季度淨虧損9450.3萬元】百濟神州公告，2025年第一季度實現營業總收入80.48億元，同比增長50.2%；產品收入79.85億元，同比增長49.9%；營業利潤1.51億元，去年同期為虧損18.3億元；歸屬於母公司所有者的淨利潤虧損9450.3萬元，去年同期虧損19.08億元；產品收入增長主要得益於自研產品百悅澤®和百澤安®的銷售增長。

百濟神州：2025年第一季度淨虧損9450.3萬元

百濟神州(06160)第一季度總收入11.17億美元同比增加49%

【香港恒生指數收漲0.13% 恒生科技指數跌0.75%】香港恒生指數收漲0.13%，恒生科技指數跌0.75%。博雷頓上市首日漲超38%，弘業期貨漲超34%；百濟神州跌超7%，藥明生物跌超6%，泡泡瑪特跌超5%。

A股創新藥概念午後持續下挫，百濟神州跌近9%，榮昌生物、益方生物、一品紅、信立泰、迪哲醫藥等多股跌超5%。

【創新藥概念持續調整百濟神州跌近9%】午後創新藥概念持續下挫，百濟神州跌近9%，榮昌生物、益方生物、一品紅、信立泰、迪哲醫藥等多股跌逾5%。

長城證券行業報告本週醫藥板塊上漲0.49%，百濟神州BCL-2抑制劑申報上市醫藥吳明華,陳玥樺 20250506

百濟神州2024年年報點評：營收大幅增長，2025年將迎來 GAAP經營性利潤轉正【東吳醫藥朱國廣團

国广有话说

百濟神州總裁吳曉濱：將醫療信息進行整合並發現規律，可為人類健康帶來巨大福祉

累虧超600億元！市值卻超3600億元

中国基金报

百濟神州勝訴

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ONC/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百濟神州","latestPrice":219.95,"timestamp":1747252800000,"preClose":224.73,"halted":0,"volume":262785,"hourTrading":{"tag":"盘后","latestPrice":219.95,"preClose":219.95,"latestTime":"18:20 EDT","volume":1825,"amount":401390.1,"timestamp":1747261215490},"delay":0,"floatShares":78938275,"shares":108055817,"eps":-3.70325,"marketStatus":"未開盤","change":-4.78,"latestTime":"05-14 16:00:00 EDT","open":223.2,"high":225.91,"low":218.31,"amount":58233410.90145,"amplitude":0.033818,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1747296000000},"marketStatusCode":0,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":224.73,"preHourTrading":{"tag":"盘前","latestPrice":224.68,"preClose":224.73,"latestTime":"09:29 EDT","volume":19,"amount":4262.519850000001,"timestamp":1747229360067},"postHourTrading":{"tag":"盘后","latestPrice":219.95,"preClose":219.95,"latestTime":"18:20 EDT","volume":1825,"amount":401390.1,"timestamp":1747261215490},"volumeRatio":0.523813,"impliedVol":0.404,"impliedVolPercentile":0.1758},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":78938275,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":0.523813,"shares":108055817,"dividePrice":0,"high":225.91,"amplitude":0.033818,"preClose":224.73,"low":218.31,"week52Low":141.31,"pbRate":"6.79","psRate":"5.69","week52High":287.88,"institutionHeld":0,"latestPrice":219.95,"eps":-3.70325,"divideRate":0,"volume":262785,"delay":0,"ttmEps":-3.70325,"open":223.2,"prevYearClose":184.71,"prevWeekClose":231.99,"prevMonthClose":259.81,"prevQuarterClose":272.17,"fiveDayClose":232.25,"twentyDayClose":238.84,"sixtyDayClose":238.11},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1161286799","title":"異動解讀 | 百濟神州股價盤前大跌5.25%，Q1財報虧損遠超預期","url":"https://stock-news.laohu8.com/highlight/detail?id=1161286799","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161286799?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 20:48","pubTimestamp":1746622111,"startTime":"0","endTime":"0","summary":"5月7日盘前，生物科技公司百济神州股价大跌5.25%，引发市场关注。这一跌幅主要受到公司最新发布的2025年第一季度财报影响，财报显示公司仍未实现盈利，且亏损幅度超出市场预期。根据百济神州公布的2025年第一季度财报，公司实现营业总收入80.48亿元，同比增长50.2%；产品收入79.85亿元，同比增长49.9%。值得注意的是，创新药概念股近期整体表现疲软。这一行业整体走势也在一定程度上影响了百济神州的股价表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 百济神州股价盘前大跌5.25%，Q1财报亏损远超预期","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ONC"],"gpt_icon":1},{"id":"2533809959","title":"百濟神州第一季度淨利虧損9450.3萬元，同比大幅減虧","url":"https://stock-news.laohu8.com/highlight/detail?id=2533809959","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533809959?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 20:33","pubTimestamp":1746621226,"startTime":"0","endTime":"0","summary":"北京商报讯（记者丁宁）5月7日晚间，百济神州（688235）发布2025年第一季度主要财务数据公告显示，报告期内，公司实现营业收入80.48亿元，同比增长50.2%；归属净利润为-9450.3万元，上年同期为-19.08亿元，同比大幅减亏。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505073398350324.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505073398350324.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1588","06160","LU1969619763.USD","LU2328871848.SGD","ONC","BK1583","BK4139","BK1500","LU0588546209.SGD","BK1161","LU0307460666.USD"],"gpt_icon":0},{"id":"2533984281","title":"百濟神州(688235.SH)一季度營業總收入80.48億元，同比增長50.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533984281","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533984281?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 20:02","pubTimestamp":1746619377,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(688235.SH)布2025年第一季度主要财务数据公告，报告期内，公司实现营业总收入80.48亿元，同比增长50.2%:其中产品收入79.85亿元，同比增长49.9%。营业利润、利润总额由亏损转为盈利。产品收入的增长主要得益于公司自研产品百悦泽®(泽布替尼胶囊),以及百泽安®(替雷利珠单抗)和安进授权产品的销售增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290421.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK1500","688235","06160","LU0588546209.SGD","ONC","BK4139","BK0239","LU2328871848.SGD","LU1969619763.USD","BK1583","LU0307460666.USD","BK1161"],"gpt_icon":0},{"id":"2533905984","title":"百濟神州首次實現季度GAAP盈利一季度澤布替尼全球銷售額超50億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533905984","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533905984?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 19:47","pubTimestamp":1746618420,"startTime":"0","endTime":"0","summary":"百济神州在2025年第一季度实现首次GAAP季度盈利，营收达80.48亿元，同比增长50.2%。核心产品泽布替尼全球销售额突破56.92亿元，其中在美国市场销售额达到40.41亿元，同比增长61.9%，并成为美国CLL和BTK抑制剂市场的领导者。公司预计全年营业收入将介于352亿元至381亿元之间，并重申经营利润为正且经营活动产生现金流为正。此外，百济神州在全球六大洲的业务布局进一步加强，展示了其在肿瘤创新领域的强劲增长势头。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050719591394ef391b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050719591394ef391b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC"],"gpt_icon":0},{"id":"2533264981","title":"百濟神州（06160）2025Q1強勁增長 首次實現季度GAAP盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2533264981","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533264981?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 19:43","pubTimestamp":1746618233,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2025年5月7日，百济神州发布2025年第一季度美股业绩报告及A股业绩快报。业绩快报显示，百济神州实现营收80.48亿元，同比增长50.2%。财务表现方面，2025年第一季度，百济神州凭借全球收入的快速增长和经营费用的有效管理，在盈利方面再次取得重大进展。目前，该产品已在全球46个市场获批上市，超150万例患者接受治疗。同时，百济神州预计将于2025年下半年完成BGB-58067和BG-89894联合治疗临床试验的首例患者入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290401.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK1500","688235","06160","LU0588546209.SGD","ONC","BK4139","BK0239","LU2328871848.SGD","LU1969619763.USD","BK1583","LU0307460666.USD","BK1161"],"gpt_icon":0},{"id":"2533848699","title":"A股公告精選 | 百濟神州(688235.SH)第一季度營業利潤、利潤總額由虧轉盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2533848699","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533848699?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 19:39","pubTimestamp":1746617962,"startTime":"0","endTime":"0","summary":"今日关注百济神州、源杰科技、纬德信息等公司公告。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20250507/20250507193933_19933.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20250507/20250507193933_19933.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290396.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0588546209.SGD","BK0239","LU0307460666.USD","LU1969619763.USD","06160","LU2328871848.SGD","BK1588","BK1500","688235","399300","BK4139","BK1583","159982","ONC","BK1161"],"gpt_icon":0},{"id":"2533098132","title":"百濟神州：第一季度淨虧損9450.3萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533098132","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533098132?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 19:23","pubTimestamp":1746616993,"startTime":"0","endTime":"0","summary":"每经AI快讯，百济神州5月7日发布2025年第一季度主要财务数据公告，报告期内，公司实现营业总收入80.48亿元，同比增长50.2%；归属于母公司所有者的净利润为-9450.3万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505073398303029.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505073398303029.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0307460666.USD","LU2328871848.SGD","ONC","06160","BK1588","BK1500","LU0588546209.SGD","BK1583","LU1969619763.USD","BK1161","BK4139"],"gpt_icon":0},{"id":"2533983707","title":"百濟神州Q1營收增長50.2%至80.48億元，百悅澤®全球銷售額總計56.92億","url":"https://stock-news.laohu8.com/highlight/detail?id=2533983707","media":"财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533983707?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 19:05","pubTimestamp":1746615944,"startTime":"0","endTime":"0","summary":"5月7日，百济神州发布2025年一季报。披露公司Q1营收增长50.2%至80.48亿元，净亏损9450.3万元。2025年第一季度，百悦泽全球销售额总计56.92亿元，同比增长63.7%，在血液肿瘤领域进一步巩固领导地位。中国销售额总计5.90亿元，同比增长43.1%，主要得益于该产品在已获批适应症领域的销售增长。百悦泽临床开发项目迄今已在全球超过30个国家和地区开展超过35项试验，入组约7,100例患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050719061994ef2bc1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050719061994ef2bc1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","06160"],"gpt_icon":0},{"id":"2533865329","title":"百濟神州、宜聯新藥IND！禮來重金加註、AZ聯合療法新進展","url":"https://stock-news.laohu8.com/highlight/detail?id=2533865329","media":"医药经济报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533865329?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 19:02","pubTimestamp":1746615770,"startTime":"0","endTime":"0","summary":"百济神州1类新药获批临床日前，CDE官网公示，百济神州申报的1类新药BGB-45035片就新适应症获得临床试验默示许可，拟开发治疗结节性痒疹。本次BGB-45035针对结节性痒疹新适应症获批临床，意味着该产品的临床开发迎来新的进展。此前，Alchemab宣布与礼来达成协议。值得一提的是，根据ECHO的结果，阿可替尼联合苯达莫司汀和利妥昔单抗疗法已于2025年1月17日获FDA批准用于MCL一线治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507191622a475488d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250507191622a475488d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BFTCPJ56.SGD","IE00B2B36J28.USD","SG9999014906.USD","LLY","LU1720051017.SGD","LU1868836591.USD","LU2237443382.USD","LU2491050154.USD","IE00B1BXHZ80.USD","LU2237438978.USD","688235","SG9999001176.SGD","LU0289739699.SGD","SG9999014880.SGD","LU0106261372.USD","LU1720051108.HKD","LU0203201768.USD","SG9999015978.USD","LU0122379950.USD","SG9999001176.USD","LU1917777945.USD","IE00BK4W5L77.USD","LU0820561818.USD","LU2471134952.CNY","LU2552382215.SGD","LU2264538146.SGD","SG9999014914.USD","LU0471298777.SGD","LU2112291526.USD","ONC","LU0198837287.USD","LU0354030438.USD","LU2237443978.SGD","LU1267930730.SGD","LU0882574139.USD","LU2211815571.USD","LU0640476718.USD","LU2361044865.SGD","AZ","LU2491050071.SGD","GB00BDT5M118.USD","BK4187","LU2237443549.SGD","LU0266013472.USD","LU1093756168.USD","LU2602419157.SGD","06160","LU2750360641.GBP","IE0004445239.USD","SGXZ99366536.SGD","LU1093756325.SGD","BK4533"],"gpt_icon":1},{"id":"2533998339","title":"【百濟神州：2025年第一季度淨虧損9450.3萬元】百濟神州公告，2025年第一季度實現營業總收入80.48億元，同比增長50.2%；產品收入79.85億元，同比增長49.9%；營業利潤1.51億元，去年同期為虧損18.3億元；歸屬於母公司所有者的淨利潤虧損9450.3萬元，去年同期虧損19.08億元；產品收入增長主要得益於自研產品百悅澤®和百澤安®的銷售增長。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533998339","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533998339?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 18:57","pubTimestamp":1746615437,"startTime":"0","endTime":"0","summary":"百济神州公告，2025年第一季度实现营业总收入80.48亿元，同比增长50.2%；产品收入79.85亿元，同比增长49.9%；营业利润1.51亿元，去年同期为亏损18.3亿元；归属于母公司所有者的净利润亏损9450.3万元，去年同期亏损19.08亿元；产品收入增长主要得益于自研产品百悦泽®和百泽安®的销售增长。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/07185750201368.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ONC","688235","06160"],"gpt_icon":0},{"id":"2533988218","title":"百濟神州：2025年第一季度淨虧損9450.3萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533988218","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533988218?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 18:57","pubTimestamp":1746615436,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["688235","LU2328871848.SGD","ONC","BK1588","06160","LU0588546209.SGD","BK1161","LU1969619763.USD","BK0239","BK4139","BK1583","LU0307460666.USD","BK1500"],"gpt_icon":0},{"id":"2533904604","title":"百濟神州(06160)第一季度總收入11.17億美元 同比增加49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533904604","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533904604?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 18:10","pubTimestamp":1746612621,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州 发布2025年第一季度业绩，该集团取得总收入11.17亿美元，同比增加49%;GAAP净利润127万美元，去年同期则亏损2.51亿美元;经调整净利润1.36亿美元，去年同期则取得亏损1.46亿美元; GAAP基本每股美国存托股份收益0.01美元。公告称，总收入的增长主要得益于百悦泽在美国和欧洲的销售额增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290295.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1500","688235","BK1161","06160","ONC","LU0588546209.SGD","BK1583","LU2328871848.SGD","BK1588","LU1969619763.USD","BK4139","LU0307460666.USD","BK0239"],"gpt_icon":0},{"id":"2533673292","title":"【香港恒生指數收漲0.13% 恒生科技指數跌0.75%】香港恒生指數收漲0.13%，恒生科技指數跌0.75%。博雷頓上市首日漲超38%，弘業期貨漲超34%；百濟神州跌超7%，藥明生物跌超6%，泡泡瑪特跌超5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533673292","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533673292?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 16:10","pubTimestamp":1746605453,"startTime":"0","endTime":"0","summary":"香港恒生指数收涨0.13%，恒生科技指数跌0.75%。博雷顿上市首日涨超38%，弘业期货涨超34%；百济神州跌超7%，药明生物跌超6%，泡泡玛特跌超5%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d308e1e0dcbd1f45bcee5ecd29af9255","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/07161050191141.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["HSTECH","HSI","LU1720050803.USD","001236","02269","LU2039709279.SGD","LU1969619763.USD","LU2328871848.SGD","LU1242518931.SGD","03678","LU0572944931.SGD","LU0417516902.SGD","HHImain","BK1592","LU0819121731.USD","LU0979878070.USD","BK1564","MCHmain","LU1242518857.USD","LU0856984785.SGD","LU0348825331.USD","09992","LU0348735423.USD","BK1147","LU0359202008.SGD","BK1175","LU0516422440.USD","LU0417516738.SGD","LU1880383366.USD","BK1589","LU0326950275.SGD","688235","IE00B0JY6N72.USD","LU0456827905.SGD","LU0823426480.USD","513600","06160","LU0140636845.USD","BK1161","BK1576","02833","BK1583","LU0307460666.USD","LU0516422366.SGD","LU0359201612.USD","LU0348767384.USD","ONC","LU0516423091.SGD","LU0039217434.USD"],"gpt_icon":0},{"id":"2533623745","title":"A股創新藥概念午後持續下挫，百濟神州跌近9%，榮昌生物、益方生物、一品紅、信立泰、迪哲醫藥等多股跌超5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533623745","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533623745?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 13:56","pubTimestamp":1746597395,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["688235","LU0588546209.SGD","LU1064131003.USD","BK1588","300723","06978","BK4139","BK0239","688192","BK1161","BK0183","BK0188","ONC","BK0028","BK1583","BK1500","LU2148510915.USD","09995","002294","LU1969619763.USD","159992","688382","LU2328871848.SGD","06160","159982","BK1574","399300","BK0187","BK0196","LU0307460666.USD","LU1064130708.USD","688331"],"gpt_icon":0},{"id":"2533253366","title":"【創新藥概念持續調整 百濟神州跌近9%】午後創新藥概念持續下挫，百濟神州跌近9%，榮昌生物、益方生物、一品紅、信立泰、迪哲醫藥等多股跌逾5%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2533253366","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533253366?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 13:54","pubTimestamp":1746597245,"startTime":"0","endTime":"0","summary":"午后创新药概念持续下挫，百济神州跌近9%，荣昌生物、益方生物、一品红、信立泰、迪哲医药等多股跌逾5%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/07135450187475.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09995","BK0028","BK0187","688192","BK0183","LU2328871848.SGD","ONC","06160","688382","BK1500","BK1583","BK0188","688331","LU0307460666.USD","LU1064130708.USD","BK4139","BK0196","688235","LU2148510915.USD","159992","300723","LU0588546209.SGD","BK0239","BK1588","BK1574","LU1064131003.USD","06978","BK1161","LU1969619763.USD","002294"],"gpt_icon":0},{"id":"2533618671","title":"長城證券*行業報告*本週醫藥板塊上漲0.49%，百濟神州BCL-2抑制劑申報上市*醫藥*吳明華,陳玥樺 20250506","url":"https://stock-news.laohu8.com/highlight/detail?id=2533618671","media":"长城证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533618671?lang=zh_tw&edition=fundamental","pubTime":"2025-05-07 08:45","pubTimestamp":1746578753,"startTime":"0","endTime":"0","summary":"报告名称: 本周医药板块上涨0.49%，百济神州BCL-2抑制剂申报上市报告类型: 行业报告报告日期: 20250506研究员: 吴明华,陈玥桦行业: 医药投资评级：强于大市(维持)本周申万医药生物板块涨幅为0.49%，跑赢沪深300指数0.93个百分点，在31个申万一级行业涨跌幅中排名第9位。二级子板块中，医药商业上涨3.12%；医疗服务上涨1.69%；化学制药上涨0.82%；医疗器械上涨0.61%；生物制品下跌0.87%；中药II下跌1.01%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050708460597513e38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050708460597513e38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0276","159938","688235","002939","06160","ONC","BK0239"],"gpt_icon":0},{"id":"2533634234","title":"百濟神州2024年年報點評：營收大幅增長，2025年將迎來 GAAP經營性利潤轉正【東吳醫藥朱國廣團","url":"https://stock-news.laohu8.com/highlight/detail?id=2533634234","media":"国广有话说","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533634234?lang=zh_tw&edition=fundamental","pubTime":"2025-05-06 21:30","pubTimestamp":1746538248,"startTime":"0","endTime":"0","summary":"投资要点事件：公司4月底发布2024年年报，公司2024年实现收入272.1亿元，同比+56.2%。归母净利润-49.8亿元，进一步减亏，全年实现非GAAP经营性利润为正。得益于泽布替尼全球销售的快速增长，业绩略 超市 场预期。公司2025年全年收入指引为49亿至53亿美金，GAAP经营性利润转正。泽布替尼全球销售快速增长，BCL2抑制剂和BTK CDAC巩固血液瘤领军地位。泽布替尼目前已在70+市场获批，在美国CLL新患者治疗中处于领先地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506214115a6d51b3a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506214115a6d51b3a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","ONC"],"gpt_icon":0},{"id":"2533506576","title":"百濟神州總裁吳曉濱：將醫療信息進行整合並發現規律，可為人類健康帶來巨大福祉","url":"https://stock-news.laohu8.com/highlight/detail?id=2533506576","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533506576?lang=zh_tw&edition=fundamental","pubTime":"2025-05-06 17:20","pubTimestamp":1746523200,"startTime":"0","endTime":"0","summary":"　　4月21日，2025年中国绿公司年会聚焦“医疗健康与生命科学”主题举办高级别闭门研讨。百济神州总裁、首席运营官吴晓滨作题为《创新药的发展与思考》的演讲。　　吴晓滨说，当今无论是发达国家还是发展中国家，有约 80% 的国家所面临的医疗状况与我国十几年前相似——进口药品价格高昂。如果能够整合并结构化处理这些数据，其中蕴含着大量未被发现的生命奥秘和疾病治疗规律，将会对中国人民乃至全人类的健康带来巨大的福祉。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2025-05-06/doc-inevrkva2208050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","LU2328871848.SGD","BK1500","LU0307460666.USD","06160","LU0588546209.SGD","159891","BK1588","BK4139","LU1969619763.USD","BK1161","688235","ONC","BK1583","02197"],"gpt_icon":0},{"id":"2532397845","title":"累虧超600億元！市值卻超3600億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532397845","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532397845?lang=zh_tw&edition=fundamental","pubTime":"2025-05-04 13:59","pubTimestamp":1746338381,"startTime":"0","endTime":"0","summary":"百济神州4月28日晚发布的2024年年报显示，2024年公司亏损49.78亿元，是2024年亏损金额最多的医药上市公司；累计未弥补亏损为626.67亿元。2024年，恒瑞医药实现营业收入279.85亿元，同比增长22.63%；归属于上市公司股东的净利润为63.37亿元，同比增长47.28%。2024年，百利天恒营业收入为58.23亿元、同比增长936.31%；净利润达37.08亿元，同比增长575.02%；毛利率达95.46%，超过贵州茅台的91.93%。文章来源：中国基金报累亏超600亿元！","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250504141916a471a5a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250504141916a471a5a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONC","688235","06160"],"gpt_icon":0},{"id":"2532360144","title":"百濟神州勝訴","url":"https://stock-news.laohu8.com/highlight/detail?id=2532360144","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532360144?lang=zh_tw&edition=fundamental","pubTime":"2025-05-04 10:01","pubTimestamp":1746324060,"startTime":"0","endTime":"0","summary":"百济神州宣布胜诉，USPTO裁定Pharmacyclics的‘803专利无效，该专利是艾伯维子公司对百济神州产品百悦泽®提出的侵权指控的核心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050410061594ebdeda&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050410061594ebdeda&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","06160","BK0239"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盤前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盤前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"盤前","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-05-11","symbol":"ONC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1715400000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.6818,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6818,"analysts":22,"updateTime":1744084800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-05-13","current":-64.235992,"percent":0.011364,"low":-64.911375,"twenty":-43.211621,"median":-38.58804,"eighty":-28.814932,"high":-22.805663,"avg":-37.142289,"sd":9.154987,"marketCap":25204019315},"quantilePoints":[{"date":"2025-01-03","current":-23.85925,"twenty":-23.85925,"median":-23.85925,"eighty":-23.85925,"marketCap":19590153584},{"date":"2025-01-10","current":-23.169003,"twenty":-23.588216,"median":-23.51181,"eighty":-23.096335,"marketCap":18938568040},{"date":"2025-01-17","current":-26.770744,"twenty":-26.217794,"median":-23.689854,"eighty":-23.142836,"marketCap":21882666138},{"date":"2025-01-24","current":-28.798988,"twenty":-27.60701,"median":-25.13119,"eighty":-23.374687,"marketCap":23683664763},{"date":"2025-01-31","current":-29.253094,"twenty":-28.895055,"median":-26.770744,"eighty":-23.516999,"marketCap":24179205805},{"date":"2025-02-07","current":-29.699946,"twenty":-29.114029,"median":-28.456686,"eighty":-23.723733,"marketCap":24422582437},{"date":"2025-02-14","current":-29.279798,"twenty":-29.132261,"median":-28.781271,"eighty":-23.9826,"marketCap":24061904635},{"date":"2025-02-21","current":-31.546239,"twenty":-29.269116,"median":-28.798062,"eighty":-24.917918,"marketCap":26058437677},{"date":"2025-02-28","current":-46.072488,"twenty":-30.312806,"median":-28.916244,"eighty":-26.238043,"marketCap":29706894943},{"date":"2025-03-07","current":-42.702936,"twenty":-33.205878,"median":-29.060335,"eighty":-26.487572,"marketCap":27534255325},{"date":"2025-03-14","current":-42.304107,"twenty":-40.627279,"median":-29.228112,"eighty":-26.926934,"marketCap":27277096074},{"date":"2025-03-21","current":-43.63686,"twenty":-41.989697,"median":-29.279798,"eighty":-27.60701,"marketCap":28136436571},{"date":"2025-03-28","current":-43.795471,"twenty":-42.273573,"median":-29.808923,"eighty":-28.393975,"marketCap":28238706493},{"date":"2025-04-04","current":-44.082326,"twenty":-43.290212,"median":-30.877376,"eighty":-28.597906,"marketCap":28423666794},{"date":"2025-04-11","current":-34.741183,"twenty":-42.946887,"median":-33.164233,"eighty":-28.695114,"marketCap":22400628140},{"date":"2025-04-17","current":-38.113584,"twenty":-42.748137,"median":-33.549429,"eighty":-28.784295,"marketCap":24575105056},{"date":"2025-04-25","current":-42.900785,"twenty":-42.748137,"median":-34.741183,"eighty":-28.796727,"marketCap":27661825682},{"date":"2025-05-02","current":-42.724352,"twenty":-42.75242,"median":-37.447221,"eighty":-28.798247,"marketCap":27548064220},{"date":"2025-05-09","current":-64.911375,"twenty":-42.880619,"median":-38.484462,"eighty":-28.804303,"marketCap":25469016595},{"date":"2025-05-13","current":-64.235992,"twenty":-43.211621,"median":-38.58804,"eighty":-28.814932,"marketCap":25204019315}],"updateTime":1747290983548}}}